p-aminohippuric acid
Small moleculeapproved
Approved
Dec 30, 1944
Aminohippurate (p-aminohippuric acid, PAH, PAHA) is the glycine amide of p-aminobenzoic acid. Aminohippuric acid sodium salt is an agent to measure effective renal plasma flow (ERPF). — NCATS
Clinical trial activity
14 trials · 14 clinical orgs · 2 marketing orgs
Phase 1
6
Phase 2
4
Phase 3
0
Phase 4
3
Earliest trial started Jul 1, 1999 (NCT00431665)
Timeline
Indications
Studied for
- Bariatric Surgery · Phase 1/Phase 2
- Cardiovascular Diseases · Phase 1
- Diabetes Complications · Phase 1/Phase 2
- Diabetes Mellitus · Phase 1/Phase 2
- Diabetes Mellitus, Type 1 · Phase 1/Phase 2
- Diabetes Mellitus, Type 2 · Phase 2
- Diabetic Nephropathies · Phase 2
- Endothelial Cells · Phase 1
- Healthy Volunteers · Phase 4
- Heart Failure · Phase 4
- Hypertension · Phase 1
- Insulin Resistance · Phase 1
- Kidney Diseases · Phase 1/Phase 2
- Obesity · Phase 1/Phase 2
- Pediatric Obesity · Phase 1/Phase 2
- Tuberculosis · Phase 1
- Weight Loss · Phase 1/Phase 2
Mechanism of action
- Glycine maxBINDING AGENT
Glycine max binding agent
Approval history
- approvedDec 30, 1944
Chemistry & pharmacology
Loading structure…
SMILES
Nc1ccc(C(=O)NCC(=O)O)cc1- Mol. weight
- 194.19 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
- Delivery
- Parenteral
- Availability
- Discontinued
Oral
No
Parenteral
Yes
Topical
No
Sources
- ChEMBLCHEMBL463 ↗
- WikipediaAminohippuric acid ↗
- NCATSY79XT83BJ9 ↗
- ChEMBLCHEMBL1200365 ↗
Also known as
- 4-aminohippuric acid
- 4-aminohippuric acid
- 4-aminohippuric acid
- aminohippurate
- aminohippurate
- aminohippurate
- aminohippurate
- aminohippurate
- aminohippurate
- aminohippurate sodium
- aminohippurate sodium
- aminohippurate sodium
- aminohippurate sodium
- aminohippurate sodium
- aminohippuric acid
- aminohippuric acid
- aminohippuric acid
- aminohippuric acid
- aminohippuric acid
- aminohippuric acid
- n-(p-aminobenzoyl)aminoacetic acid
- n-(p-aminobenzoyl)aminoacetic acid
- n-(p-aminobenzoyl)glycine
- n-(p-aminobenzoyl)glycine
- n-(para-aminobenzoyl)glycine
- n-(para-aminobenzoyl)glycine
- pah
- pah
- paha
- paha
- paha
- p-aminohippurate
- p-aminohippurate
- p-aminohippurate sodium
- p-aminohippurate sodium
- p-aminohippuric acid
- p-aminohippuric acid
- p-aminohippuric acid
- para-aminohippurate
- para-aminohippurate
- para-aminohippurate
- para-aminohippurate sodium [injection]
- para-aminohippurate sodium [injection]
- para-aminohippuric acid
- para-aminohippuric acid
- para-aminohippuric acid
- paraaminohippuric acid
- paraaminohippuric acid
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05507892 | Phase 2 | Oct 10, 2022 | Boston University, Harvard University, University of Colorado, Denver, University of Michigan |
| NCT05065372 | Phase 1 | Jan 1, 2022 | National Heart, Lung, and Blood Institute (NHLBI), University of Colorado, Denver |
| NCT04649229 | Phase 4 | Feb 28, 2021 | Yale University |
| NCT04113109 | Phase 4 | Oct 31, 2019 | Vanderbilt University |
| NCT03618420 | Phase 1/Phase 2 (Phase 2) | Sep 30, 2018 | University of Colorado, University of Colorado, Denver |
| NCT03620773 | Phase 1/Phase 2 (Phase 2) | Sep 30, 2018 | University of Colorado, University of Colorado, Denver |
| NCT03584217 | Phase 1/Phase 2 (Phase 2) | Jul 31, 2018 | University of Colorado, University of Colorado, Denver |
| NCT01702688 | N/A | Nov 1, 2012 | Harvard University |
| NCT01156220 | Phase 4 | Jan 1, 2012 | University of Hamburg |
| NCT01214993 | Phase 1 | Oct 1, 2010 | GlaxoSmithKline, Shionogi, ViiV Healthcare |
| NCT01426529 | Phase 1 | Oct 1, 2010 | Harvard University, National Heart, Lung, and Blood Institute (NHLBI), National Institutes of Health (NIH) |
| NCT01511042 | N/A | Dec 1, 1999 | Harvard University |
| NCT01456208 | N/A | Oct 1, 1999 | Harvard University |
| NCT00431665 | N/A | Jul 1, 1999 | University of Vienna |
Showing 14 of 14 trials
Page 1 / 1
Organizations
Research & Development (14)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Harvard University | Academic/Hospital | 5 | 4 | 3 | 1999 |
| University of Colorado, Denver | Academic/Hospital | 5 | 5 | 2 | 2018 |
| University of Colorado | Academic/Hospital | 3 | 0 | 1 | 2018 |
| National Heart, Lung, and Blood Institute (NHLBI) | Government | 2 | 0 | 1 | 2010 |
| Boston University | Academic/Hospital | 1 | 0 | 1 | 2022 |
| GlaxoSmithKline | For profit | 1 | 0 | 1 | 2010 |
| National Institutes of Health (NIH) | Government | 1 | 0 | 1 | 2010 |
| Shionogi | For profit | 1 | 0 | 1 | 2010 |
| University of Hamburg | Academic/Hospital | 1 | 1 | 1 | 2012 |
| University of Michigan | Academic/Hospital | 1 | 0 | 1 | 2022 |
| University of Vienna | Academic/Hospital | 1 | 1 | 1 | 1999 |
| Vanderbilt University | Academic/Hospital | 1 | 1 | 1 | 2019 |
| ViiV Healthcare | For profit | 1 | 1 | 1 | 2010 |
| Yale University | Academic/Hospital | 1 | 1 | 1 | 2021 |
14 organizations
Page 1 / 1
Marketing (3)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| Athenex, Inc. | For profit | MKTG | — |
| Merck | For profit | NDA2 | Dec 30, 1944 |
| Merck | For profit | NDA | Dec 30, 1944 |